Biosimilar Oncology Roundup for November 2023—Podcast Edition
Season 6, Episode 21, Dec 03, 2023, 12:00 PM
On this episode, we discuss the abundance of oncology news from November, especially during Global Biosimilars Week 2023, which was themed around the growth of oncology biosimilars.
Show notes
- Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle?
- Part 1: Oncology Biosimilars Offer Comparable Benefits to Originators at Lower Prices
- Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings
- Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
- Denosumab Biosimilar Demonstrates Positive Safety Results in Chinese Study
- Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
- Similar Safety Profiles of Biosimilar, Reference Pegfilgrastim Found in Clinical Studies
- Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone